Hepatitis C Kinetics: Mathematical Modeling of Viral Response to Therapy

Thomas J. Layden; Brian Mika; Thelma E. Wiley

doi:10.1055/s-2000-9940

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2000; 20(2): 173-184
DOI: 10.1055/s-2000-9940

Hepatitis C Kinetics: Mathematical Modeling of Viral Response to Therapy

Thomas J. Layden, Brian Mika, Thelma E. Wiley

University of Illinois at Chicago, Section of Digestive and Liver Diseases, Chicago, Illinois

Abstract

ABSTRACT

Mathematical models have been used to study the dynamics of HIV. Using these same principles, the dynamics of hepatitis C virus (HCV) are reviewed during interferon (IFN) therapy. After initiating IFN treatment, there is an IFN dose-dependent exponential decline in viral RNA levels within the first 48 hours. This rapid 1.0 to 2.0 log decline was best explained by an effect of IFN in inhibiting viral production with a varying degree of effectiveness. By applying mathematical principles, viral serum half-life was estimated to be 3.0 hours and viral production rate was calculated to be 1.0 × 10¹² virions per day. After this rapid first-phase decline there was a slower second phase decline in viral levels that was highly variable between subjects. This phase was dependent on the rate of elimination of HCV-infected liver cells. The rapidity of the second phase proved to be the best predictor of early viral clearance. The use of these models to understand the life cycle of viruses and their response to therapy is reviewed.

KEYWORD

hepatitis C virus - interferon - ribavirin

Full Text

References

REFERENCES

1 Alter M J. Epidemiology of hepatitis C. Hepatology . 1997; 26(Suppl 1) 62S-65S
2 Tong M J, El-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med . 1995; 332 1463-1466
3 Liaw Y F, Tsai S L. Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection. Vital Hep Rev . 1997; 3 143-154
4 Wiley T E, McCarthy M, Breidi L. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology . 1998; 28 805-809
5 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet . 1997; 349 825-832
6 Davis G L, Albright J E, Cook S F, Rosenberg D M. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology . 1998; 28 99A
7 Poynard T, Marcellin P, Lee S S. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet . 1998; 352 1426-1432
8 McHutchinson J G, Gordon S C, Schiff E R. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med . 1998; 339 1485-1492
9 Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology . 1996; 24 778-789
10 Reddy K R, Hoofnagle J H, Tong M J. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology . 1999; 30 787-793
11 Orito E, Mizokami M, Suzuki K. Loss of serum HCV RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis. J Med Virol . 1995; 46 109-115
12 Karino Y, Toyota J, Sugawara M. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol . 1997; 92 61-65
13 Matsumoto A, Tanaka E, Suzuki T. Viral and host factors that contribute to efficacy of interferon alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci . 1994; 39 1273-1280
14 Davis G L, Esteban-Mur R, Rustgi V. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med . 1998; 339 1493-1499
15 Lam N P, Neumann A U, Gretch D R. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology . 1997; 26 226-231
16 Neumann A U, Lam N P, Dahari H. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science . 1998; 282 103-107
17 Zeuzem S, Schmidt J M, Lee J-H. Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology . 1996; 23 366-371
18 Zeuzem S, Schmidt J M, Lee J-H. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover. Hepatology . 1998; 28 245-252
19 Beckering F C, Brouwer J T, Leroux-Roels G. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in nonresponders to standard therapy. J Hepatol . 1998; 28 960-964
20 Yasui K, Okanoue T, Murakami Y. Dynamics of hepatitis C viremia following interferon-alpha administration. J Infect Dis . 1998; 177 1475-1479
21 Layden T J, Reddy R. Effects of interferon alfacon-1 (Infergen) on the viral kinetics of hepatitis C. Hepatology . 1999; 30 823
22 Ho D D, Neumann A U, Perelson A S. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature . 1995; 373 123-126
23 Perelson A S, Neumann A U, Markowitz M. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science . 1996; 271 1582-1586
24 Perelson A S, Essunger P, Cao Y. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature . 1997; 386 188-191
25 Nowak M A, Banhoeffer S, Hill A M, Boehme R, Thomas H C, McDade H. Viral dynamics in hepatitis B infection. Proc Natl Acad Sci USA . 1996; 93 4398-4402
26 Tsiang M, Rooney J F, Toole J J. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology . 1999; 29 1863-1869
27 Wiley T E, Briedi L, Lam N. Early HCV RNA values after interferon predicts response. Dig Dis Sci . 1998; 43 2169-2172
28 Tong M J, Reddy K R, Lee W M. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology . 1997; 26 747-754
29 Bekkering F C, Brouwer J T, Niesters H GM. Viral kinetics in HCV genotype 1:L is the second phase of viral decline interferon dose dependent?. Hepatology . 1999; 30 124
30 Chen R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminas level as a determinant for hepatitis B Antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology . 1999; 30 770-774
31 Lok A SF, Chang M G, Watson G. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat . 1998; 5 171-178
32 Gale M J, Korth M J, Tang N M. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology . 1997; 230 217-227
33 Sen G C, Lengyel P. The interferon system: A bird's eye view of its biochemistry. J Biol Chem . 1992; 267 5017-5020
34 Enomoto N, Sakuma I, Asahina Y. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest . 1995; 96 224-230
35 Enomoto N, Sakuma I, Asahina Y. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med . 1996; 334 77-81
36 Khorsi H, Castelain S, Wyseu A. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol . 1997; 27 72-77
37 Duverlie G, Khorsi H, Castelain, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol . 1998; 79 1373-1381
38 Squardrito J, Leon F, Sartori M. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology . 1997; 113 567-572
39 Franguel L, Cresta P, Perrin M. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Hepatology . 1998; 28 1674-1679
40 Paterson M, Laxton C D, Thomas H C. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology . 1999; 117 1187-1197
41 Taylor D R, Shi S T, Romano P R. Inhibition of the interferon inducible protein kinase PKR by HCV E2 protein. Science . 1999; 285 107-110
42 Lam N P, Neumann A U, Dahari H. Early viral decline slopes during daily high dose interferon (IFN) are predictive markers of subsequent virologic response. Hepatology . 1998; 28 397A
43 Mika B B, Lam N P, McCarthy M E. Pretreatment histological activity index (HAI) is an indicator of early HCV viral clearance with IFN therapy. Accepted for oral presentation to the American association for the study of liver diseases. Gastroenterology . 1999; 116 A1246
44 Nelson D R, Marousis C G, Ohno T. Intrahepatic hepatitis C virus-specific cytotoxic t lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology . 1998; 28 225-230
45 Nelson D R, Marousis C G, Davis G L. The role of hepatitis C virus-specific cytotoxic t lymphocytes in chronic hepatitis C. J Immunol . 1997; 158 1473-1481
46 Koziel M J, Dudley D, Afdhal N. Hepatitis C virus (HCV) specific cytotoxic T lymphocyte recognize epitopes in the core and envelope proteins of HCV. J Virol . 1993; 67 7522-7532
47 Koziel M J, Dudley D, Wong J T. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol . 1992; 149 3339-3344
48 Cerny A, Chisari F V. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology . 1999; 30 595-601
49 Lau J YN. Mechanisms of hepatic toxicity IV. Pathogenetic mechanisms involved in hepatitis C virus-induced liver diseases. Pathogene Hepat C. 1998; G1217-G1220
50 Kohara M, Tanaka T, Tsukiyama-Kohara K. Hepatitis C virus genotypes 1 and 2 respond to interferon-α with different virologic kinetics. JID. 1995; 172 934-938
51 Neumann A U, Lam N P, Davidian M. Differences in hepatitis C virus (HCV) dynamics between HCV of genotype 1 and genotype 2. Hepatology . 1999; 30 121
52 Hattori M, Yoshioka K, Aiyama T. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: Relation to viral loads and response to interferon. Hepatology . 1998; 27 1703-1710
53 Mondelli M U, Cerino A, Brambilla S. Antibody responses to hepatitis C virus hypervariable region 1: Evidence for cross-reactivity and immune-mediated sequence variation. Hepatology . 1999; 3 537-545
54 Missale G, Cariani E, Lamonaca V. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b and genotype 2c infected patients. Hepatology . 1997; 26 792-797
55 Neumann A U, Dahari H, Conrad A. Early prediction and mechanism of the ribavirin/IFN-α dual therapy effect on chronic hepatitis C virus (HCV) infection. Hepatology . 1999; 30 595